ISAB has received a new order for its in vitro technology from a regional distributor in Asia worth 94,000 USD. It is the second order from the region in one week.

Investment and innovation in inhaled therapies has increased significantly in Asia-Pacific over recent years. In September 2022, for example, China approved the world's first inhaled Covid-19 vaccine for emergency use (1).

The advantages of in vitro testing in inhalation drug development are becoming increasingly understood and prioritized in the industry. In vitro dissolution testing that can for example generate predictive IVIVC (in vitro in vivo correlated) data early on, can significantly reduce risks and costs, accelerating the development of both novel and inhaled generics. ISAB has two different in vitro testing systems in its product portfolio.

CEO Manoush Masarrat: "We have been working closely with our local distributors over a long time now and I am delighted to see a second order from the Asian market. We look forward to see our technology play a part in developing vital new therapies in this dynamic region."

1. CNN - https://edition.cnn.com/2022/09/06/china/china-covid-19-vaccine-cansino-intl-hnk/index.html